RNA Day is on Sunday, August 1st this year, and we welcome the international celebration of one of the most versatile biomolecules we have seen come to life.
We have seen RNA play a key role in addressing the COVID-19 global pandemic as the world’s first approved mRNA vaccines have given us our best chance to escape the grip of the virus.
With this newfound respect for RNA among the general public, it’s no wonder that RNA-based vaccines and therapeutics for other disease areas have also gained major interest. mRNA vaccines are in clinical trials to conquer respiratory syncytial virus, cytomegalovirus, HIV, influenza, and other viruses. mRNA-based therapeutics are also in development for cancer, rare diseases, and more.
Recognizing the rapidly expanding interest in RNA-based vaccine and biologics development, we’re proud to announce that our BioXp platform now enables researchers to go from digital sequence to synthesized mRNA in a single overnight run and help accelerate the development of these emerging vaccines and therapies.
In addition, Codex DNA supports researchers who need critical diagnostic testing tools to detect the presence of the SARS-CoV-2 virus. We introduced SARS-CoV-2 RNA controls useful for quality control measures for the verification and validation of both NGS and RT-PCR diagnostic assays. We have also partnered with the scientific community to release full-length synthetic genomes for the emerging SARS-CoV-2 variants, including the Alpha and Beta variants originally identified in the UK and South Africa. The genomes were synthesized de novo on our BioXp™ 3250 system and made available to use for developing vaccines, therapeutics, and diagnostics associated with COVID-19.
On RNA Day, we’re taking the opportunity to honor the tremendous efforts of decades of science that have made new advances in RNA-based therapeutics possible, and we’re also looking forward to how we can continue to partner with members of the scientific community using RNA to address many pressing health challenges.
Happy RNA Day, everyone!